Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Return on Sales (2016 - 2025)

Zevra Therapeutics' Return on Sales history spans 9 years, with the latest figure at 0.36% for Q4 2025.

  • For Q4 2025, Return on Sales rose 333.0% year-over-year to 0.36%; the TTM value through Dec 2025 reached 0.78%, up 526.0%, while the annual FY2025 figure was 0.78%, 525.0% up from the prior year.
  • Return on Sales reached 0.36% in Q4 2025 per ZVRA's latest filing, up from 0.02% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 2.88% in Q2 2025 to a low of 53.79% in Q3 2022.
  • Average Return on Sales over 5 years is 5.08%, with a median of 0.97% recorded in 2021.
  • Peak YoY movement for Return on Sales: plummeted -5289bps in 2022, then surged 5021bps in 2023.
  • A 5-year view of Return on Sales shows it stood at 1.05% in 2021, then surged by 72bps to 0.3% in 2022, then tumbled by -418bps to 1.54% in 2023, then tumbled by -93bps to 2.97% in 2024, then soared by 112bps to 0.36% in 2025.
  • Per Business Quant, the three most recent readings for ZVRA's Return on Sales are 0.36% (Q4 2025), 0.02% (Q3 2025), and 2.88% (Q2 2025).